SCHEMBL8240495

SCHEMBL8240495

Clc1nc(-c2ccccc2)cn2c(I)cnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.43
PIM1 P11309 2/20 0.43
CSNK1D P48730 2/20 0.43
CLK2 P49760 2/20 0.43
STK3 Q13188 2/20 0.43
RPS6KB1 P23443 1/20 0.43
IRAK4 Q9NWZ3 1/20 0.43
FGFR1 P11362 2/20 0.40
NTRK1 P04629 1/20 0.40
IGF1R P08069 1/20 0.40
LTK P29376 1/20 0.40
MAP2K2 P36507 1/20 0.40
MAPK9 P45984 1/20 0.40
RPS6KA3 P51812 1/20 0.40
PRKX P51817 1/20 0.40
PRKCQ Q04759 1/20 0.40
TNK2 Q07912 1/20 0.40
NPC1 O15118 4/20 0.40
RAB9A P51151 4/20 0.40
SMN1; SMN2 Q16637 4/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8246186 0.82 IDO1 (0.37) NPC1RAB9ASMN1; SMN2ALDH1A1KDM4E
SCHEMBL8240027 0.82 CLK4 (0.40) CLK4PIM1CSNK1DCLK2STK3
SCHEMBL9938786 0.78 TTK (0.52) CLK4PIM1CSNK1DCLK2STK3
SCHEMBL9937210 0.76 TTK (0.53) CLK4PIM1CSNK1DCLK2STK3
SCHEMBL9937411 0.72 TTK (0.56)
SCHEMBL8240567 0.71 CDK2 (0.47) PRKCQFYNSRCGSK3BBLK
SCHEMBL8240139 0.69 GSK3B (0.48) CLK4NPC1RAB9AMEN1KMT2A
SCHEMBL8240492 0.69 TMIGD3 (0.52) NPC1RAB9ASMN1; SMN2ALDH1A1HPGD
SCHEMBL3524705 0.69 PDE5A (0.51) CLK4PIM1CSNK1DCLK2STK3
SCHEMBL2817874 0.68 ADORA2A (0.64) ALDH1A1HPGDKDM4EADORA2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576085-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2009-08-18 US disclosed
US-7576085-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2009-08-18 US disclosed
US-7432265-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-7432265-B2 Imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION (US) 2008-10-07 US disclosed
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2006-05-18 US disclosed
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2006-05-18 US disclosed
US-20040063715-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2004-04-01 US disclosed
US-20040063715-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors SCHERING CORPORATION 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063715-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors CDK2, CDKN1A, CDK1 CLK4 365/4885PIM1 154/4885CSNK1D 139/4885
US-20060106023-A1 Novel imidazopyrazines as cyclin dependent kinase inhibitors CDK2, CDKN1A, CDK1 CLK4 300/4885PIM1 217/4885CSNK1D 132/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.